Xu CW, Ding RJ, Xu CP. Analysis of the effects of different surgical procedures for the treatment of thyroid cancer on the expression levels of IL-17, IL-35, and SIL-2R and the prognostic factors. Oncologie. 2020;22(1):43–51.
Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J National Cancer Center. 2022;2(1):1–9.
Isik A, Soran A, Grasi A, Barry N, Sezgin E. Lymphedema after sentinel lymph node biopsy: who is at risk? Lymphat Res Biol. 2022;20(2):160–3.
Isik A, Firat D, Yilmaz I, Peker K, Idiz O, Yilmaz B, et al. A survey of current approaches to thyroid nodules and thyroid operations. Int J Surg. 2018;54(Pt A):100–4.
Isik A, Wysocki AP, Memiş U, Sezgin E, Yezhikova A, Islambekov Y. Factors associated with the occurrence and healing of umbilical pilonidal sinus: a rare clinical entity. Adv Skin Wound Care. 2022;35(8):1–4.
Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223(2):102–15.
Chandra S, Vimal D, Sharma D, Rai V, Gupta SC, Chowdhuri DK. Role of miRNAs in development and disease: lessons learnt from small organisms. Life Sci. 2017;185:8–14.
Pinto Y, Buchumenski I, Levanon EY, Eisenberg E. Human cancer tissues exhibit reduced A-to-I editing of miRNAs coupled with elevated editing of their targets. Nucleic Acids Res. 2018;46(1):71–82.
Di Fiore R, Drago-Ferrante R, Pentimalli F, et al. Let-7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma-derived 3AB-OS cancer stem cells. J Cell Physiol. 2016;231(8):1832–41.
Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751–6.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. The Papanicolaou Society of Cytopathology Task Force on standards of practice. Diagn Cytopathol. 1996;15:84–9.
Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1–10.
Thakur S, Saini A-K, Das J, Saini V, Balhara P, Nanda J-S, et al. miR-153 as biomarker for cancer—functional role as tumor suppressor. Biocell. 2022;46(1):13–26.
Chen X, Zhang H, Li L, Chen W, Bao T, Li B. miR-5100 mediates migration and invasion of melanomatous cells in vitro via targeting SPINK5. J Comprehens Mol Sci Genet. 2021;1:14–23.
Eisfeld AK, Kohlschmidt J, Schwind S, et al. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017;31(6):1278–85.
Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2018;156(2):585–94.
Deng M, Qin Y, Chen X, Wang Q, Wang J. MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the MUC1 gene. Onco Targets Ther. 2019;12:849–59.
Lyu J, Sun Y, Li X, Ma H. MicroRNA-206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the c-met/AKT/GSK-3β pathway. Oncol Lett. 2021;21(2):147.
Liao M, Peng L. MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C. Cell Mol Biol Lett. 2020;25:22.
Zheng Y, Zhao C, Zhang N, Kang W, Lu R, Wu H, et al. Serum microRNA miR-206 is decreased in hyperthyroidism and mediates thyroid hormone regulation of lipid metabolism in HepG2 human hepatoblastoma cells. Mol Med Rep. 2018;17(4):5635–41.
Liu F, Yin R, Chen X, Chen W, Qian Y, Zhao Y, et al. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 2019;114:108605.
Trimboli P, Scappaticcio L, Treglia G, Guidobaldi L, Bongiovanni M, Giovanella L. Testing for BRAF (V600E) mutation in thyroid nodules with fine-needle aspiration (FNA) read as suspicious for malignancy (Bethesda V, Thy4, TIR4): a systematic review and meta-analysis. Endocr Pathol. 2020;31(1):57–66.
Xiao Y, Zhou P, Zheng YZ, Zheng C, Liu GW, Liu WX. A nomogram for predicting lateral lymph node metastasis in cases of papillary thyroid micro-carcinoma with suspected lymph node metastasis. Oncologie. 2021;23(2):219–28.
Mazeh H, Deutch T, Karas A, Bogardus KA, Mizrahi I, Gur-Wahnon D, et al. Next-generation sequencing identifies a highly accurate miRNA panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules. Cancer Epidemiol Biomark Prev. 2018;27(8):858–63.